Background: Hypertrophic cardiomyopathy is the most prevalent heart disorder in cats and principal cause of cardiovascular morbidity and mortality. Yet, the impact of preclinical disease is unresolved. Hypothesis/Objectives: Observational study to characterize cardiovascular morbidity and survival in cats with preclinical nonobstructive (HCM) and obstructive (HOCM) hypertrophic cardiomyopathy and in apparently healthy cats (AH). Animals: One thousand seven hundred and thirty client-owned cats (430 preclinical HCM; 578 preclinical HOCM; 722 AH). Methods: Retrospective multicenter, longitudinal, cohort study. Cats from 21 countries were followed through medical record review and owner or referring veterinarian interviews. Data were analyzed to compare long-term outcomes, incidence, and risk for congestive heart failure (CHF), arterial thromboembolism (ATE), and cardiovascular death. Results: During the study period, CHF, ATE, or both occurred in 30.5% and cardiovascular death in 27.9% of 1008 HCM/HOCM cats. Risk assessed at 1, 5, and 10 years after study entry was 7.0%/3.5%, 19.9%/9.7%, and 23.9%/11.3% for CHF/ATE, and 6.7%, 22.8%, and 28.3% for cardiovascular death, respectively. There were no statistically significant differences between HOCM compared with HCM for cardiovascular morbidity or mortality, time from diagnosis to development of morbidity, or cardiovascular survival. Cats that developed cardiovascular morbidity had short survival (mean ± standard deviation, 1.3 ± 1.7 years). Overall, prolonged longevity was recorded in a minority of preclinical HCM/HOCM cats with 10% reaching 9-15 years. Conclusions and Clinical Importance: Preclinical HCM/HOCM is a global health problem of cats that carries substantial risk for CHF, ATE, and cardiovascular death. This finding underscores the need to identify therapies and monitoring strategies that decrease morbidity and mortality.
International Collaborative Study to Assess Cardiovascular Risk and Evaluate Long-term Health in Cats with Pre-clinical Hypertrophic Cardiomyopathy and Apparently Healthy Cats : The REVEAL Study / P. Fox, B. Keene, K. Lamb, K. Schober, V. Chetboul, V. Luis Fuentes, G. Wess, J. Payne, D. Hogan, A. Motsinger-Reif, J. Häggström, E. Trehiou-Sechi, D. Fine-Ferreira, R. Nakamura, P. Lee, M. Singh, W. Ware, J. Abbott, G. Culshaw, S. Riesen, M. Borgarelli, M. Lesser, N. Van Israel, E. Cote, J. Rush, B. Bulmer, R. Santilli, A. Vollmar, M. Bossbaly, N. Quick, C. Bussadori, J. Bright, A. Estrada, D. Ohad, M.J. Fernández del Palacio, J. Lunney Brayley, D. Schwartz, C. Bove, S. Gordon, S. Jung, P. Brambilla, N.S. Moise, C. Stauthammer, R. Stepien, C. Quintavalla, C. Amberger, F. Manczur, Y. Hung, R. Lobetti, M. De Swarte, A. Tamborini, C. Mooney, M. Oyama, A. Komolov, Y. Fujii, R. Pariaut, M. Uechi, V.Y. Tachika Ohara. - In: JOURNAL OF VETERINARY INTERNAL MEDICINE. - ISSN 1939-1676. - 32:3(2018 May), pp. 930-943. [10.1111/jvim.15122]
International Collaborative Study to Assess Cardiovascular Risk and Evaluate Long-term Health in Cats with Pre-clinical Hypertrophic Cardiomyopathy and Apparently Healthy Cats : The REVEAL Study
P. Brambilla;
2018
Abstract
Background: Hypertrophic cardiomyopathy is the most prevalent heart disorder in cats and principal cause of cardiovascular morbidity and mortality. Yet, the impact of preclinical disease is unresolved. Hypothesis/Objectives: Observational study to characterize cardiovascular morbidity and survival in cats with preclinical nonobstructive (HCM) and obstructive (HOCM) hypertrophic cardiomyopathy and in apparently healthy cats (AH). Animals: One thousand seven hundred and thirty client-owned cats (430 preclinical HCM; 578 preclinical HOCM; 722 AH). Methods: Retrospective multicenter, longitudinal, cohort study. Cats from 21 countries were followed through medical record review and owner or referring veterinarian interviews. Data were analyzed to compare long-term outcomes, incidence, and risk for congestive heart failure (CHF), arterial thromboembolism (ATE), and cardiovascular death. Results: During the study period, CHF, ATE, or both occurred in 30.5% and cardiovascular death in 27.9% of 1008 HCM/HOCM cats. Risk assessed at 1, 5, and 10 years after study entry was 7.0%/3.5%, 19.9%/9.7%, and 23.9%/11.3% for CHF/ATE, and 6.7%, 22.8%, and 28.3% for cardiovascular death, respectively. There were no statistically significant differences between HOCM compared with HCM for cardiovascular morbidity or mortality, time from diagnosis to development of morbidity, or cardiovascular survival. Cats that developed cardiovascular morbidity had short survival (mean ± standard deviation, 1.3 ± 1.7 years). Overall, prolonged longevity was recorded in a minority of preclinical HCM/HOCM cats with 10% reaching 9-15 years. Conclusions and Clinical Importance: Preclinical HCM/HOCM is a global health problem of cats that carries substantial risk for CHF, ATE, and cardiovascular death. This finding underscores the need to identify therapies and monitoring strategies that decrease morbidity and mortality.
| File | Dimensione | Formato | |
|---|---|---|---|
|
REVEAL study.pdf
accesso aperto
Tipologia:
Pre-print (manoscritto inviato all'editore)
Dimensione
1.68 MB
Formato
Adobe PDF
|
1.68 MB | Adobe PDF | Visualizza/Apri |
|
Fox_et_al-2018-Journal_of_Veterinary_Internal_Medicine.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
2.15 MB
Formato
Adobe PDF
|
2.15 MB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
